Interview
CEO Mike Kujak Interviewed by Medtech Insight
August 6, 2024
In a recent exclusive interview with Citeline Commercial’s Medtech Insight, Mike Kujak, CEO of Francis Medical, revealed the latest developments regarding Vanquish—our revolutionary advancement for treating prostate cancer with water vapor therapy. Kujak’s insights offer a glimpse into how this innovative device is set to redefine standards in prostate cancer treatment.
Medtech Insight Article: Vanquishing Prostate Cancer Without Debilitating Side Effects – Francis Medical CEO On Water Vapor Ablation
More on Mike on our Leadership Page
Recent Posts
Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc.,a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System
Press Release: Francis Medical Announces Completion of Enrollment in the VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
Press Release: Francis Medical Announces Close of Record $80 Million Series C Equity Financing
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.